健康社会决定因素与急性髓系白血病患者接受异基因造血细胞移植的可及性
该研究前瞻性纳入13个急性髓系白血病治疗中心的692例患者,分析健康社会决定因素与异基因造血细胞移植可及性及结局的关联。结果显示教育程度低和贫困程度高的地区患者未接受移植的死亡风险增加、接受移植的可能性降低,而移植后死亡风险增加幅度较小。作者认为需要针对性干预和政策变革以确保边缘化患者群体获得公平的治愈机会。
要点
- 教育程度低于高中比例每增加10%,未接受移植死亡的风险比(aHR)为1.21(0.99-1.46)。
- 贫困比例每增加10%,未接受移植死亡的风险比(aHR)为1.16(0.96-1.39),接受移植的aHR为0.91(0.75-1.09)。
- 接受移植后死亡的风险比在教育程度低(aHR 1.18,0.87-1.60)和贫困(aHR 1.04,0.79-1.36)方面增加幅度较小。
核心结论
- 来自教育资源有限和/或贫困程度较高地区患者未接受移植的死亡风险增加、接受移植的可及性降低,但移植后死亡风险增加幅度较小。
- 作者认为需要针对性干预和政策变革以确保边缘化患者群体与其他人群具有公平的急性髓系白血病治愈机会。
研究设计与样本
- 前瞻性招募至注册临床试验(NCT01929408)的患者,来自13个急性髓系白血病治疗中心,共692例。
- 收集患者、急性髓系白血病及健康社会决定因素相关变量,结局包括未接受移植的死亡、接受移植及移植后死亡。
- 对每个健康社会决定因素变量分别拟合多变量模型(前两个结局用Fine-Gray模型,第三个用Cox回归),并校正相关患者和急性髓系白血病特异性变量。
主要发现
- 46%的患者接受了异基因造血细胞移植。
- 教育程度低于高中比例每增加10%,未接受移植死亡的校正风险比(aHR)为1.21(0.99-1.46)。
- 补充营养援助计划领取比例每增加10%,未接受移植死亡的aHR为1.13(0.97-1.31),接受移植的aHR为0.88(0.76-1.01)。
- 补充保障收入领取比例每增加10%,未接受移植死亡的aHR为1.41(1.01-1.97),接受移植的aHR为0.71(0.48-1.05)。
- 贫困比例每增加10%,未接受移植死亡的aHR为1.16(0.96-1.39),接受移植的aHR为0.91(0.75-1.09)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Whether allogeneic hematopoietic cell transplant (allo-HCT) to treat acute myeloid leukemia (AML) is equitably accessible regardless of social determinants of health (SDOH) remains unknown. We examined associations of SDOH with access to allo-HCT and other outcomes. Patients presenting for treatment (n = 692) at 13 AML treatment centers were prospectively recruited to a registered clinical trial (number NCT01929408). Various patient-, AML-, and SDOH-specific variables were collected. Outcomes included mortality without allo-HCT, receipt of allo-HCT, and mortality after allo-HCT. Individual multivariable models (Fine-Gray for the first 2 outcomes, Cox regression for the third) were fit for each SDOH variable, adjusting for relevant patient- and AML-specific variables. Allo-HCT was used to treat 46% of patients. A 10% increase in the proportion with less than a high school education, in households receiving Supplemental Nutrition Assistance Program, receiving Supplemental Security Income, or in poverty led to modeled adjusted hazard ratios (aHRs) of 1.21 (0.99-1.46), 1.13 (0.97-1.31), 1.41 (1.01-1.97), and 1.16 (0.96-1.39) for death without allo-HCT. The aHRs were 0.67 (0.55-0.83), 0.88 (0.76-1.01), 0.71 (0.48-1.05), and 0.91 (0.75-1.09) for lessened receipt of allo-HCT. Among those who received allo-HCT, aHRs for mortality were 1.18 (0.87-1.60), 1.13 (0.92-1.38), 1.21 (0.81-1.82), and 1.04 (0.79-1.36). Results highlight increased mortality without allo-HCT and decreased access to allo-HCT, but lesser magnitude of increased mortality after allo-HCT, among patients from lower resourced areas due to limited education and/or increased poverty. Targeted interventions and policy changes are needed to ensure that marginalized patient populations have equitable chances for AML cure compared with others.
引用
- Wuliji N, Jones SMW, Gooley T, et al. Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Blood. 2025. PMID: 40067123. doi:10.1182/blood.2024027543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。